Literature DB >> 17483925

Cellular and molecular responses in progressive pseudorheumatoid dysplasia articular cartilage associated with compound heterozygous WISP3 gene mutation.

Hou-De Zhou1, Yan-Hong Bu, Yi-Qun Peng, Hui Xie, Min Wang, Lin-Qing Yuan, Yi Jiang, Duo Li, Qi-You Wei, Yu-Ling He, Tao Xiao, Jiang-Dong Ni, Er-Yuan Liao.   

Abstract

Progressive pseudorheumatoid dysplasia (PPD) is characterized by continuous degeneration and loss of articular cartilage, which has been attributed to mutations in the gene encoding WISP3. We collected a PPD family and analyzed their WISP3 genes mutation. Articular chondrocytes (ACs) were purified from the femurs of a PPD patient after hip replacement surgery. Cell growth, proliferation, and viability were examined. Gene expression profiling and analyses of matrix metalloproteinases (MMP)-1, -3, and -13 proteins were carried out using cDNA differential microarrays, real-time reverse transcriptase-polymerase chain reaction (RT-PCR), immunohistochemistry, and Western blot analysis. We found that two probands carried a deletion (840delT) mutation in maternal allele, which leads to truncated WISP3 protein missing 43 residues in C terminus; and a 1000T>C substitution in paternal allele, which was also passed on to four other members in the PPD kindred. PPD ACs were heterogeneous in size with an enhanced rate of cell proliferation and viability compared with the normal ACs. MMP-1, -3, and -13 mRNA expressions were dereased in PPD ACs. MMP-1, -3, and -13 protein levels, however, were increased in cell lysates from PPD ACs, but markedly decreased in the supernatants from cultured ACs. WISP3 mRNA expression in PPD ACs was also decreased. Our results show, for the first time, a compound heterozygous mutation of WISP3 and a series of cellular and molecular changes disturbing the endochondral ossification in this PPD patient.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17483925     DOI: 10.1007/s00109-007-0193-2

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  35 in total

1.  Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints.

Authors:  M W Lark; E K Bayne; J Flanagan; C F Harper; L A Hoerrner; N I Hutchinson; I I Singer; S A Donatelli; J R Weidner; H R Williams; R A Mumford; L S Lohmander
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

Review 2.  The role of collagenolytic matrix metalloproteinases in the loss of articular cartilage in osteoarthritis.

Authors:  Gerald N Smith
Journal:  Front Biosci       Date:  2006-09-01

Review 3.  Matrix metalloproteinases: role in skeletal development and growth plate disorders.

Authors:  Charles J Malemud
Journal:  Front Biosci       Date:  2006-05-01

4.  Spondylo-epiphyseal dysplasia tarda with progressive arthropathy mimicking juvenile chronic arthritis.

Authors:  P A Byrne; K T Rajan
Journal:  Br J Rheumatol       Date:  1998-02

5.  Collagenase-3 (MMP-13) is expressed during human fetal ossification and re-expressed in postnatal bone remodeling and in rheumatoid arthritis.

Authors:  M Ståhle-Bäckdahl; B Sandstedt; K Bruce; A Lindahl; M G Jiménez; J A Vega; C López-Otín
Journal:  Lab Invest       Date:  1997-05       Impact factor: 5.662

6.  MMP13 mutation causes spondyloepimetaphyseal dysplasia, Missouri type (SEMD(MO).

Authors:  Ann M Kennedy; Masaki Inada; Stephen M Krane; Paul T Christie; Brian Harding; Carlos López-Otín; Luis M Sánchez; Anna A J Pannett; Andrew Dearlove; Claire Hartley; Michael H Byrne; Anita A C Reed; M Andrew Nesbit; Michael P Whyte; Rajesh V Thakker
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

7.  Differential matrix degradation and turnover in early cartilage lesions of human knee and ankle joints.

Authors:  Matthias Aurich; Ginette R Squires; Agnes Reiner; Juergen A Mollenhauer; Klaus E Kuettner; A Robin Poole; Ada A Cole
Journal:  Arthritis Rheum       Date:  2005-01

8.  Histamine stimulates the proliferation of human articular chondrocytes in vitro and is expressed by chondrocytes in osteoarthritic cartilage.

Authors:  L C Tetlow; D E Woolley
Journal:  Ann Rheum Dis       Date:  2003-10       Impact factor: 19.103

9.  Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage.

Authors:  P G Mitchell; H A Magna; L M Reeves; L L Lopresti-Morrow; S A Yocum; P J Rosner; K F Geoghegan; J E Hambor
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

Review 10.  Articular cartilage and changes in arthritis: matrix degradation.

Authors:  J S Mort; C J Billington
Journal:  Arthritis Res       Date:  2001-09-06
View more
  11 in total

1.  Dual regulation of metalloproteinase expression in chondrocytes by Wnt-1-inducible signaling pathway protein 3/CCN6.

Authors:  Natasha Baker; Paul Sharpe; Kirsty Culley; Miguel Otero; Damon Bevan; Peter Newham; Wendy Barker; Kristen M Clements; Caroline J Langham; Mary B Goldring; Jelena Gavrilović
Journal:  Arthritis Rheum       Date:  2012-07

2.  Novel COL2A1 variant (c.619G>A, p.Gly207Arg) manifesting as a phenotype similar to progressive pseudorheumatoid dysplasia and spondyloepiphyseal dysplasia, Stanescu type.

Authors:  Julie Jurgens; Nara Sobreira; Peggy Modaff; Catherine A Reiser; Soo Hyun Seo; Moon-Woo Seong; Sung Sup Park; Ok Hwa Kim; Tae-Joon Cho; Richard M Pauli
Journal:  Hum Mutat       Date:  2015-08-06       Impact factor: 4.878

Review 3.  Progressive pseudorheumatoid dysplasia: a rare childhood disease.

Authors:  Sofia Torreggiani; Marta Torcoletti; Belinda Campos-Xavier; Francesco Baldo; Carlo Agostoni; Andrea Superti-Furga; Giovanni Filocamo
Journal:  Rheumatol Int       Date:  2018-10-16       Impact factor: 2.631

4.  A retrospective study of nine patients with progressive pseudorheumatoid dysplasia: to explore early diagnosis and further treatment.

Authors:  Lei Yin; Youying Mao; Yunfang Zhou; Yongnian Shen; Huijin Chen; Wei Zhou; Yanliang Jin; Hua Huang; Yongguo Yu; Jian Wang
Journal:  Clin Rheumatol       Date:  2021-10-21       Impact factor: 2.980

5.  The CCN family member Wisp3, mutant in progressive pseudorheumatoid dysplasia, modulates BMP and Wnt signaling.

Authors:  Yukio Nakamura; Gilbert Weidinger; Jennifer O Liang; Allisan Aquilina-Beck; Keiko Tamai; Randall T Moon; Matthew L Warman
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

6.  CCN6 mutation detection in Chinese patients with progressive pseudo-rheumatoid dysplasia and identification of four novel mutations.

Authors:  Yingjie Wang; Ke Xiao; Yuemei Yang; Zhihong Wu; Jin Jin; Guixing Qiu; Xisheng Weng; Xiuli Zhao
Journal:  Mol Genet Genomic Med       Date:  2020-04-29       Impact factor: 2.183

7.  Normal growth and development in mice over-expressing the CCN family member WISP3.

Authors:  Yukio Nakamura; Yajun Cui; Carol Fernando; Wendy E Kutz; Matthew L Warman
Journal:  J Cell Commun Signal       Date:  2009-04-29       Impact factor: 5.782

8.  Dysfunction of collagen synthesis and secretion in chondrocytes induced by wisp3 mutation.

Authors:  Min Wang; Xiao-Fei Man; Ya-Qing Liu; Er-Yuan Liao; Zhi-Feng Shen; Xiang-Hang Luo; Li-Juan Guo; Xian-Ping Wu; Hou-De Zhou
Journal:  Int J Endocrinol       Date:  2013-03-19       Impact factor: 3.257

9.  Delayed-onset of progressive pseudorheumatoid dysplasia in a Chinese adult with a novel compound WISP3 mutation: a case report.

Authors:  Qiongyi Hu; Jing Liu; Yi Wang; Jiucun Wang; Hui Shi; Yue Sun; Xinyao Wu; Chengde Yang; Jialin Teng
Journal:  BMC Med Genet       Date:  2017-12-15       Impact factor: 2.103

10.  Progressive pseudorheumatoid dysplasia with new-found gene mutation of Wntl inducible signaling pathway protein 3.

Authors:  Wenji Chen; Shiyan Mo; Gui Luo; Yanyan Wang; Xiaohu Deng; Jian Zhu; Wei Zhao
Journal:  Pediatr Rheumatol Online J       Date:  2018-09-10       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.